The list price of the therapy for A.L.S., Relyvrio, is $158,000 a year. To make matters worse, the drug was approved by the Food and Drug Administration even though the agency’s analysis concluded there was not yet sufficient evidence that the medication could help patients live longer or slow the rate at which they lose functions like muscle control, speaking or breathing without assistance.